Comparative effectiveness of axitinib versus sorafenib in advanced renal cell carcinoma (AXIS): a randomised phase 3 trial. - Wikidata - awgldk - TriplyDB

Comparative effectiveness of axitinib versus sorafenib in advanced renal cell carcinoma (AXIS): a randomised phase 3 trial.

Comparative effectiveness of axitinib versus sorafenib in advanced renal cell carcinoma (AXIS): a randomised phase 3 trial.

http://www.wikidata.org/entity/Q34633525

about

Mutational profiling of kinases in glioblastoma.Hard-Wired Bias: How Even Double-Blind, Randomized Controlled Trials Can Be Skewed From the Start A comprehensive overview of targeted therapy in metastatic renal cell carcinoma State of the science: an update on renal cell carcinoma Immunobiology and immunotherapy in genitourinary malignancies Contemporary Treatment of Metastatic Renal Cell Carcinoma Comparative efficacy and safety of axitinib versus sorafenib in metastatic renal cell carcinoma: a systematic review and meta-analysis Recent advances in the management of renal cell carcinoma Axitinib in the treatment of renal cell carcinoma: patient selection and perspectives Beyond evidence-based data: scientific rationale and tumor behavior to drive sequential and personalized therapeutic strategies for the treatment of metastatic renal cell carcinoma Chinese guidelines on the management of renal cell carcinoma (2015 edition)Sequence of treatment in locally advanced and metastatic renal cell carcinoma Current management and future directions in the treatment of advanced renal cell carcinoma-a latin american perspective: 10 years in review Targeting PD-1/PD-L1 in the treatment of metastatic renal cell carcinoma What links BRAF to the heart function? New insights from the cardiotoxicity of BRAF inhibitors in cancer treatment Influence of companion diagnostics on efficacy and safety of targeted anti-cancer drugs: systematic review and meta-analyses Therapeutic challenges in renal cell carcinoma Multidisciplinary management of clear-cell renal cell carcinoma in Africa and the Middle East: current practice and recommendations for improvement Profile of tivozanib and its potential for the treatment of advanced renal cell carcinoma Risk of Infectious Complications in Hemato-Oncological Patients Treated with Kinase Inhibitors Metastatic renal cell carcinoma: update on epidemiology, genetics, and therapeutic modalities Subverting the B7-H1/PD-1 pathway in advanced melanoma and kidney cancer Differentiating mTOR inhibitors in renal cell carcinoma Renal tumors: diagnostic and prognostic biomarkers Frontiers in clinical and molecular diagnostics and staging of metastatic clear cell renal cell carcinoma PD-1 as an emerging therapeutic target in renal cell carcinoma: current evidence Kidney cancer Targeted therapies and the treatment of non-clear cell renal cell carcinoma Pharmacogenetic biomarkers for the prediction of response to antiangiogenic treatment Axitinib in Metastatic Renal Cell Carcinoma Tyrosine kinase inhibitors induced thyroid dysfunction: a review of its incidence, pathophysiology, clinical relevance, and treatment Incidence and risk of sorafenib-induced hypertension: a systematic review and meta-analysis Therapy management of cardiovascular adverse events in the context of targeted therapy for metastatic renal cell carcinoma Targeted therapeutic strategies for the management of renal cell carcinoma Individualising treatment choices in a crowded treatment algorithm Circulating biomarkers in advanced renal cell carcinoma: clinical applications Clinical investigation of receptor and non-receptor tyrosine kinase inhibitors for the treatment of epithelial ovarian cancer Checkpoint modulation--A new way to direct the immune system against renal cell carcinoma Evaluating the safety and efficacy of axitinib in the treatment of advanced renal cell carcinoma Molecular conformations, interactions, and properties associated with drug efficiency and clinical performance among VEGFR TK inhibitors

P2860

Q21261249-A9CF00B6-2836-4FE6-AC8C-FBF428D866D2 Q24289425-8523B38F-FBF6-4D25-82C6-14FA091872BB Q24606852-6D86C30D-6CBB-4368-8E87-286A117B14DD Q24630685-DC4D8A5D-443F-4F68-BEB3-681D7B22866D Q26738668-7351AAAD-3570-4517-ACDC-687DDFA100B7 Q26740594-62BC9D27-74F9-4009-BDDC-C3DA1B7BADFA Q26746200-BE26779C-BF45-4F6B-9A22-32A78CC7CE14 Q26750609-719EB2D0-D5CE-4C0A-A3E5-E08DE417468C Q26751341-5038423B-F11F-450D-A10C-EB604B6AE8BA Q26766240-B3EA50E4-57D9-4B58-A90E-16413AA77B86 Q26772206-13A70977-933C-45DE-A16E-E1424E9D311C Q26773653-44620E68-23E5-41E2-8C19-793C75B15478 Q26774515-067A755E-8A3E-4C7C-B842-92E8ACEA067E Q26775769-E0FE6E5F-8AA8-48EE-B686-81845545CE43 Q26782585-AB33CC5B-AD52-47CB-B74D-D25969B000AA Q26786243-1EF9384B-42AC-4102-B239-5D7F9E952F06 Q26796702-6E690CE2-7CE6-4736-9F73-B59351F2494D Q26801279-12098A32-9906-4EB7-BD15-BE17F6AB269D Q26827319-CE165A8A-1A73-43A9-98C7-E4CE3BEA87BA Q26851417-D246D03E-447C-4C1E-AD0A-BFDDBB08E285 Q26852437-FE96BD3D-4ED8-4F75-9C22-0342263817CC Q26852704-98F64EC1-5401-4014-9A14-6CC5D7990AD2 Q26860172-D3BF67F7-F3E7-46D5-AC5F-DBDAD1662B67 Q26860500-C341055F-4F02-489B-BF3B-E4E208E828C9 Q26863402-4F375892-84BB-4F59-B75B-72F8F66011F6 Q26865789-DD8C0093-7962-45F3-9378-E60E76DED7B3 Q26866709-4CFCE5B8-25EA-4E41-87DB-288570DBB07B Q26995391-5E626173-E532-4B21-B567-541DA357767F Q26996793-CAA202ED-2F2A-45FF-9E9B-F52E39AF3B83 Q26998017-D3EAB338-23C7-40CB-81F7-4D255FF788B5 Q26998914-A4E26C03-3403-475C-8C31-5E75BF546CB6 Q27003304-8DD53405-B9DE-4DD9-86F1-5631EFC31F65 Q27013665-3026CBC8-D16B-42DB-A15C-A1D0E9D1D165 Q27013846-BCF82E2F-B21C-45EA-88EC-0ABD2FF5C217 Q27023669-92DC188D-B1D4-408D-BBBD-BF29C344B8E4 Q27023770-BE785AEA-7752-4D66-BF09-8A65E21456C8 Q27024235-5C33A397-5A1E-4E65-949A-5AFF34229EB4 Q27025873-1B0EB82B-7D26-47DB-BABE-2FFCB0BBAF19 Q27028048-43E457C9-1A57-443E-B632-20660369A982 Q27673353-7E930384-8DF4-42B8-877D-9706DD85D016

P2860

Comparative effectiveness of axitinib versus sorafenib in advanced renal cell carcinoma (AXIS): a randomised phase 3 trial.

http://www.wikidata.org/entity/Q34633525

description

2011 nî lūn-bûn

@nan

2011 թուականի Նոյեմբերին հրատարակուած գիտական յօդուած

@hyw

2011 թվականի նոյեմբերին հրատարակված գիտական հոդված

@hy

2011年の論文

@ja

2011年論文

@yue

2011年論文

@zh-hant

2011年論文

@zh-hk

2011年論文

@zh-mo

2011年論文

@zh-tw

2011年论文

@wuu

name

Comparative effectiveness of a ...... ): a randomised phase 3 trial.

@ast

Comparative effectiveness of a ...... ): a randomised phase 3 trial.

@en

Comparative effectiveness of axitinib versus sorafenib in advanced renal cell carcinoma

@nl

type

label

Comparative effectiveness of a ...... ): a randomised phase 3 trial.

@ast

Comparative effectiveness of a ...... ): a randomised phase 3 trial.

@en

Comparative effectiveness of axitinib versus sorafenib in advanced renal cell carcinoma

@nl

prefLabel

Comparative effectiveness of a ...... ): a randomised phase 3 trial.

@ast

Comparative effectiveness of a ...... ): a randomised phase 3 trial.

@en

Comparative effectiveness of axitinib versus sorafenib in advanced renal cell carcinoma

@nl

P1433

Q34633525-A380260F-7901-483E-B51D-DC3A49327C42

P1476

Q34633525-CDE0917E-EA62-428E-82E2-FE0FB5C09DD5

P2093

Q34633525-0170FC97-AD95-401A-A653-AC32CE5A688B

Q34633525-0DB55368-1E57-4310-8D59-874868BBA22D

Q34633525-3CCFC89B-DF1C-451D-8537-9CC6C49A49AD

Q34633525-5393272E-6949-41F8-86BE-37039EAA9EE3

Q34633525-56A6B06C-7983-4B4F-86F3-F7EC7E7DE178

Q34633525-57B20087-2656-40E1-9CB8-B395AAFD94C2

Q34633525-597D31F2-9487-473C-89B4-907218DDA01C

Q34633525-68BAB1D8-15F0-4C4B-AFE9-62456038908F

Q34633525-70C0C0FB-EEA6-4CC2-8545-D48E3307E6B7

Q34633525-76B32238-B2A0-463C-BFC2-9E9EA61B8992

P304

Q34633525-F0A276BF-4F18-4A8E-A71F-60B4AE479F3A

P31

Q34633525-0B978E47-1610-4676-8631-A0B0C08C2FC3

P356

Q34633525-E530CB39-D31C-42D7-B15D-FF9C6B2C8BDC

P407

Q34633525-C25356EF-67E0-4A30-A4FF-92BBBF7884AD

P433

Q34633525-AF8F7F38-4284-43BB-AC85-3C43E6878AFD

P478

Q34633525-77F86EB1-2647-4C8B-8D3F-7D5EB52C643C

P50

Q34633525-1463D399-C55C-4C03-B590-31B8DF4A5519

Q34633525-85B4F782-C579-494A-A4A9-852C4F0E5659

Q34633525-998507A7-17BD-4303-8CFC-4AFB0149BC39

P577

Q34633525-A8721249-2838-43A5-82A7-6BD4540C3C23

P698

Q34633525-ED0827A2-2E70-46C6-AD79-3FAB9F604CE2

P921

Q34633525-0E2181FD-BB0A-4ED8-B493-F57F51A93552

P356

S0140-6736(11)61613-9

P1433

P1476

Comparative effectiveness of a ...... S): a randomised phase 3 trial

@en

P2093

Bernard Escudier

http://www.w3.org/2001/XMLSchema#string

Brad Rosbrook

http://www.w3.org/2001/XMLSchema#string

Brian I Rini

http://www.w3.org/2001/XMLSchema#string

Cezary Szczylik

http://www.w3.org/2001/XMLSchema#string

Connie Chen

http://www.w3.org/2001/XMLSchema#string

Daniel Castellano

http://www.w3.org/2001/XMLSchema#string

David Cella

http://www.w3.org/2001/XMLSchema#string

Hirotsugu Uemura

http://www.w3.org/2001/XMLSchema#string

Ho Yeong Lim

http://www.w3.org/2001/XMLSchema#string

Igor G Rusakov

http://www.w3.org/2001/XMLSchema#string

P304

1931-1939

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1016/S0140-6736(11)61613-9

http://www.w3.org/2001/XMLSchema#string

P407

P433

9807

http://www.w3.org/2001/XMLSchema#string

P478

378

http://www.w3.org/2001/XMLSchema#string

P50

M. Dror Michaelson

P577

2011-11-04T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

22056247

http://www.w3.org/2001/XMLSchema#string

P921

phase III clinical trial